Highly Efficient Bifunctional Peptides for Tumor Immunotherapy by Simultaneously Activating T Cells and Blocking PD-L1 Immune Checkpoint
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c03021 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Aixian Zheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical Unive…. Hauptthemen laut MEDLINE: Immunotherapy, B7-H1 Antigen, Peptides, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Scientific Foundation of Fuzhou Municipal Health commission.
Abstract (Originalsprache)
Immune checkpoint inhibitors represented by PD-1/PD-L1 monoclonal antibodies have shown great success in tumor immunotherapy. However, the response rate of immune checkpoint blockade (ICB) therapy alone is far from satisfactory due to insufficient and exhausted tumor-infiltrating T cells. Meanwhile, antibody-based drugs have some drawbacks such as high cost and complicated preparation, which require further development of nonantibody immune checkpoint inhibitors and more rational strategies for improving the effectiveness of tumor treatment. Here, a highly efficient bifunctional peptide (Bi-pep) was constructed for tumor treatment by simultaneously activating T cells and blocking the PD-L1 immune checkpoint. This peptide not only can block the PD-1/PD-L1 immunosuppressive pathway but also directly and efficiently promote the activation and proliferation of T cells, thereby showing a significant effect on promoting T cell killing of tumor cells. The Bi-pep-induced antitumor effect was verified on both subcutaneous and orthotopic tumor models, which can significantly inhibit tumor growth and thus prolong the survival of tumor-bearing mice, holding great potential for biomedical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350007, P. R. China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou 350116, P. R. China.
- Key Laboratory of Gastrointestinal Cancer, Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, P. R. China.
ORCID-Profile: Aixian Zheng, Ming Wu, Da Zhang, Xiaolong Liu
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- Scientific Foundation of Fuzhou Municipal Health commission
- Fuzhou ?14th Five-Year? clinical key specialty
- Fujian Provincial Clinical Research Center for Hepatobiliary and Pancreatic Tumors
- Young and Middle-aged major scientific project of Fujian Provincial Health Commission
Zitieren
APA
Zheng, A., Wang, X., Wu, Y., Lan, J., Wu, M., Zhang, D., Zhang, F., Liu, X., & Zeng, Y. (2025). Highly Efficient Bifunctional Peptides for Tumor Immunotherapy by Simultaneously Activating T Cells and Blocking PD-L1 Immune Checkpoint. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c03021
Vancouver
Zheng A, Wang X, Wu Y, Lan J, Wu M, Zhang D, et al. Highly Efficient Bifunctional Peptides for Tumor Immunotherapy by Simultaneously Activating T Cells and Blocking PD-L1 Immune Checkpoint. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c03021
BibTeX
@article{Zheng2025,
author = {Zheng, Aixian and Wang, Xiaorong and Wu, Yaning and Lan, Jing and Wu, Ming and Zhang, Da and Zhang, Fangrong and Liu, Xiaolong and Zeng, Yongyi},
title = {Highly Efficient Bifunctional Peptides for Tumor Immunotherapy by Simultaneously Activating T Cells and Blocking PD-L1 Immune Checkpoint},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c03021}
}
EUVIMED